



NOVACYT ANNOUNCES INITIAL COVERAGE BY ORIEL SECURITIES

Paris, France and Cambridge, UK – 22nd January 2015 – Novacyt (ISIN Code: FR0010397232 - Mnemonic code: ALNOV), an international specialist in cancer and infectious disease diagnostics, today announces that Oriel Securities, a stock market research firm, based in London, has initiated research coverage of Novacyt.

Novacyt develops, manufactures and supplies in vitro diagnostic tests to diagnostic laboratories. The recently merged entity combines Novacyt, which develops a novel cervical screening cytology system with lab21 and its portfolio of infectious disease tests, established distribution network and revenue stream.

- Ends -

About Novacyt Group

The Novacyt Group is a leader in the field of cellular diagnostics with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform NovaPrep® and a strong international network Novacyt is able to provide an extensive range of oncology and infectious disease products. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.

For more information please refer to the website: www.novacyt.com

Contacts:

International media and investor enquiries:

International Investor & Media
Tony Stephenson
Exitus Communications
+44 (0)7899 796655
tony@exituscommunications.co.uk

French Investor & Media

Antoine Denry / Emmanuel Huynh,
NewCap
+33 (0)1 44 71 94 95
novacyt@newcap.fr

NOVACYT

Graham Mullis
Chief Executive Officer
+44 7901 514121
Graham.mullis@novacyt.com